Last $0.44 USD
Change Today +0.01 / 2.33%
Volume 505.3K
ONCS On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 8:10 PM 10/17/14 All times are local (Market data is delayed by at least 15 minutes).

oncosec medical inc (ONCS) Snapshot

Open
$0.43
Previous Close
$0.43
Day High
$0.46
Day Low
$0.43
52 Week High
03/5/14 - $0.97
52 Week Low
11/7/13 - $0.26
Market Cap
107.6M
Average Volume 10 Days
942.9K
EPS TTM
$-0.06
Shares Outstanding
244.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOSEC MEDICAL INC (ONCS)

Related News

No related news articles were found.

oncosec medical inc (ONCS) Related Businessweek News

No Related Businessweek News Found

oncosec medical inc (ONCS) Details

OncoSec Medical Incorporated, a hybrid device and gene therapy biotechnology company, designs, develops, and commercializes medical approaches principally immunotherapy for the treatment of solid tumors in the United States. Its clinical programs include three Phase II clinical trials to assess the ImmunoPulse technology in patients with melanoma, Merkel cell carcinoma, and cutaneous T-cell lymphoma. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated is headquartered in San Diego, California.

42 Employees
Last Reported Date: 10/10/14

oncosec medical inc (ONCS) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $467.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $310.0K
Chief Scientific Officer and Global Head of R...
Total Annual Compensation: $172.8K
Compensation as of Fiscal Year 2014.

oncosec medical inc (ONCS) Key Developments

OncoSec Medical Incorporated Reports Earnings Results for the Year Ended July 31, 2014

OncoSec Medical Incorporated reported earnings results for the year ended July 31, 2014. For the year, the company reported net loss of $12.0 million, or $0.06 per share, compared to a net loss of $7.2 million, or $0.07 per share, for the same period last year. The increase in net loss attributable to common stockholders, resulted primarily from an increase in salary related expenses (inclusive of stock-based compensation) due to increased headcount as the company continues to grow its company in support of corporate goals and an increase in outside services costs (sponsored research, clinical development consulting, and corporate development/communications consulting) as the company continue to expand its research and development operations and corporate infrastructure. There were no revenues for the year ended July 31, 2014 or July 31, 2013.

OncoSec Medical Inc. Appoints Sheela Mohan-Peterson as General Counsel and Corporate Secretary

OncoSec Medical Inc. has appointed Sheela Mohan-Peterson, J.D., M.S. to the position of General Counsel and Corporate Secretary. In this newly created role, she will be responsible for leading the company's global legal strategy and guiding the continued expansion of its intellectual property portfolio. Ms. Mohan-Peterson will be supported by an experienced internal legal team that includes legal associate and paralegal positions. Ms. Mohan-Peterson has spent more than 27 years working in the pharmaceutical and biotech industries, most recently as a Senior Patent Counsel with Merck & Co. Inc.

OncoSec Medical Incorporated Announces Executive Changes

OncoSec Medical Incorporated has appointed Mai H. Le, M.D. to the position of Chief Medical Officer. In this role, Dr. Le will oversee worldwide clinical development and regulatory activities for OncoSec's intratumoral cancer immunotherapy programs. In addition, Robert Pierce, M.D., who previously served as Chief Medical Officer, has been named to the newly created position of Chief Scientific Officer and Global Head of R&D. Furthermore, Tu Diep, M.Sc., who has served as Executive Director, Clinical Development, will now assume the position of Vice President of Operations. Prior to joining OncoSec, Dr. Le was medical director at Calithera Biosciences Inc., where she formulated and launched the early clinical development plans for a novel small molecule inhibitor of glutaminase for a variety of solid and hematological tumor indications.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONCS:US $0.44 USD +0.01

ONCS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONCS.
View Industry Companies
 

Industry Analysis

ONCS

Industry Average

Valuation ONCS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOSEC MEDICAL INC, please visit www.oncosec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.